TATX 19
Alternative Names: TATX-19Latest Information Update: 09 Feb 2023
At a glance
- Originator Eindhoven University of Technology; Radboud University Nijmegen Medical Centre; Talem Therapeutics
- Developer Talem Therapeutics
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 08 Feb 2023 Discontinued for COVID-2019 infections in USA (Intranasal) (Talem Therapeutics pipeline, February 2023)
- 03 Nov 2022 TATX 19 is available for licensing as of 03 Nov 2022. https://www.ipatherapeutics.com/talem-overview/talem-therapeutics-pipeline/
- 30 Dec 2020 Early research in COVID-2019 infections in USA (Intranasal)